Solventum Corporation (NYSE:SOLV) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• Analyst sentiment is moderately bullish: Eight of 13 analysts rate Solventum a buy, four recommend holding, and one rates it a sell. The average 12-month price target is $91.64, near the stock’s reported $90.86 price.
• Solventum exceeded quarterly expectations: The company reported earnings of $2.55 per share versus the $1.91 consensus estimate, while revenue rose 2.2% year over year to $2.21 billion.
• Institutional interest increased: Several investors added to or initiated positions, including Diamond Hill Capital Management and Bank of New York Mellon, while the stock traded near its 12-month high of $94.16.

Shares of Solventum Corporation (NYSE:SOLV - Get Free Report) have been given an average recommendation of "Moderate Buy" by the thirteen analysts that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and eight have issued a buy rating on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $91.6364.

A number of research analysts have issued reports on the company. Piper Sandler boosted their price target on Solventum from $92.00 to $105.00 and gave the stock an "overweight" rating in a research report on Thursday, August 6th. BTIG Research raised their price target on Solventum from $91.00 to $95.00 and gave the company a "buy" rating in a report on Thursday, August 6th. Stifel Nicolaus lifted their price objective on shares of Solventum from $90.00 to $100.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. Wedbush lifted their price objective on shares of Solventum from $94.00 to $101.00 and gave the company an "outperform" rating in a research note on Thursday, August 6th. Finally, Wells Fargo & Company reduced their price objective on shares of Solventum from $83.00 to $70.00 and set an "equal weight" rating for the company in a report on Wednesday, May 6th.

Institutional Trading of Solventum

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Diamond Hill Capital Management LLC Investment Advisor acquired a new stake in shares of Solventum in the second quarter valued at $150,066,000. SG Americas Securities LLC grew its holdings in Solventum by 38.4% during the first quarter. SG Americas Securities LLC now owns 129,663 shares of the company's stock worth $8,467,000 after acquiring an additional 35,982 shares during the period. First Trust Advisors LP grew its holdings in Solventum by 57.4% during the first quarter. First Trust Advisors LP now owns 334,441 shares of the company's stock worth $21,839,000 after acquiring an additional 121,989 shares during the period. Bank of America Corp DE raised its position in Solventum by 0.6% in the first quarter. Bank of America Corp DE now owns 1,432,780 shares of the company's stock worth $93,561,000 after acquiring an additional 9,083 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in Solventum in the second quarter worth about $61,460,000.

Solventum Stock Performance

SOLV opened at $90.86 on Wednesday. The business's 50 day moving average is $83.14 and its 200-day moving average is $75.67. The stock has a market cap of $15.47 billion, a PE ratio of 11.11, a price-to-earnings-growth ratio of 1.17 and a beta of 0.61. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 1.00. Solventum has a twelve month low of $62.38 and a twelve month high of $94.16.

Solventum (NYSE:SOLV - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $2.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.64. Solventum had a return on equity of 25.09% and a net margin of 17.26%.The business had revenue of $2.21 billion during the quarter, compared to the consensus estimate of $2.15 billion. During the same period in the previous year, the firm posted $1.69 earnings per share. The business's revenue was up 2.2% on a year-over-year basis. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. On average, analysts predict that Solventum will post 7.22 earnings per share for the current year.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source